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NERVE-MAST CELL-NERVE GROWTH FACTOR LINK: THE MAST CELL AS 
YIN-YANG MODULATOR IN INFLAMMATION AND FIBROSIS 
"Perhaps the situation at present is similar to that of the Holy elephant which had a hundred names, 
the real one being the hundred and first, known only to the elephant himself." 
Albert Szent-Gyorgyi 
Retrospect and Apology. In: Milhorat AT, editor. Exploratory concepts in muscular dys- 
trophy and related disorders. New York, Excerpta Medica Foundation, 1966; 112-114 
 
 
• Inflammation and fibroproliferation are biological re- 
sponses aiming at recovering from injury. Wound healing is 
considered a paradigm of such a homeostatic phenomenon. 
However, what begins as a protective response, in excess be- 
comes a damaging process we call chronic inflammatory-fibro- 
proliferative disease. 
Celsus's description (1st century AD) of inflammation signs 
includes rubor et tumor cum calor et dolor. For many years 
the inflammatory process has been thought of purely in terms 
of interactions involving leukocyte infiltration and fibroblast 
activation. Increasingly, however, neural cells have been shown 
to play a particularly important role in it, including interac- 
tions between nerves and mast cells (MC) (1-3). The article 
by Aloe et al (4) in this volume of Biomedical Reviews sheds 
considerable light on the potential significance of MC and 
nerve growth factor (NGF) in autoimmune-inflammatory dis- 
eases. 
Historically, the discovery of MC is usually attributed to Paul 
Ehrlich in 1878, although these cells were first recognized by 
von Recklinghausen in 1863. Ehrlich observed that MC were 
commonly located in connective tissue near blood vessels and 
nenes, as well as in inflammatory and tumor lesions. At present 
there is evidence that (i) MC can be classified into connective 
tissue and mucosal subsets, and (ii) MC synthesize and, when 
activated, release biologically active molecules, e.g. eicosa- 
noids, cytokines and growth factors, including the neurotrophic 
factors NGF (5) and leukemia inhibitory factor (LIF) (2,3). 
Last but not least, connective tissue MC are the richest cellu- 
lar source of heparin proteoglycan, histamine, tryptase and 
chymase (6), and preformed, secretion granule-stored tumor 
necrosis factor-a (TNF-a), a highly potent inflammatory and 
fibrogenic cytokine (1). 
The recent great advance relevant to MC studies occurred in 
1977 when Aloe and Levi-Montalcini established the NGF- 
induced MC proliferation in different tissues of NGF-injected 
rats (7). This insight into the biology of NGF gives a special 
meaning to the nerve-MC bidirectional link, involving an 
immunotrophic action of the classical neurotrophin NGF 
(Fig.l). Further, MC-fibroblast interactions (8) and mast cell 
growth factor (MGF; synonyms: stem cell factor, c-kit ligand; 
see Bankl et al [9] in this volume of Biomedical Reviews) were 
recognized to play a pivotal role in the biology of MC. Even 
more intriguing is the possibility that the immunotrophin MGF 
exerts a neurotrophic action (10). Thus the nerve-MC bidirec- 
tional link was further extended (Fig.2). These new concepts 
about MC, i.e. paracrine/autocrine interactions between nerves 
and MC (1-3), MC and fibroblasts (8), and nerves, MC and ef- 
fector cells (11), are now considered not only in allergic, para- 
sitic and neoplastic reactions, but also in a number of disease 
processes featured by inflammation and fibrosis (Table 1, Refs 
shown in parentheses). 
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Figure 1. Mast cells (MC) are source of and target for 
nerve growth factor (NGF). 
 
Figure 2. The nerve (N)-mast cell (MC) bidirectional 
link also involves both neurotrophic and immunotrophic 
actions of nerve growth factor (NGF) and mast cell 
growth factor (MGF). 
Possible ways of interactions between nerves, MC and cyto- 
kines, including neurotrophic factors, in the development of in- 
flammation and fibrosis are schematically presented in Fig.3,4 
(Refs shown in parentheses). We, as Aloe et al (4), suppose that 
a discordant equilibrium, in which MC-derived inflammatory 
and fibrogenic stimulators exceed inhibitors, participates in 
progression of inflammation and fibrosis. Thus, MC via synthe- 
sis and release of such molecules may be considered a modu- 
lator operating in a yin-yang manner in the regression, delay, 
or progression of these disease processes (Table 2, Refs shown 
in parentheses). Of course, other immune cells, e.g. macroph- 
ages and lymphocytes, as well as their interactions with the neu- 
roendocrine system (3 9), may also be particularly important in 
this aspect. In the context of this Editorial, it is worth mention- 
ing that the immunotrophic action of NGF involves these im- 
mune cells too (4, their Refs 37-47). 
A lot of issues can be raised in relation to the possible partici- 
pation of nerve-MC-NGF-MGF link in the pathogenesis of 
inflammatory-fibroproliferative diseases listed in Table 1. For 
example, Aloe et al (4) present data of correlative increase in 
MC number and NGF level in autoimmune diseases, but a pos- 
sible involvement of MGF remains unreported yet. Similarly, 
MGF action on cardiac MC was studied by Bankl et al (9) and 
Sperr et al (40). However, a possible importance of NGF in the 
biology of these cells was not appreciated, although a separate 
report clearly showed a significantly high NGF level in heart 
atrium (41), i.e. where a considerable amount of MC was found 
(9,40). In addition, recent reports show that NGF and other 
neurotrophins (42), including LIF (35), play an important role 
in regulating the response of vascular smooth muscle cells to 
injury. Again, inMC-rich atherosclerotic lesions (22,23), nei- 
ther NGF nor MGF were examined. Hopefully, an integrative 
research approach (cf Table 1) focusing on cardiovascular 
nerve-MC-NGF-MGF link may bring new insights into car- 
Table 1. Mast cell-associated diseases featured by inflammatory-fibroproliferative responses 
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Figure 3. Cell-mediator interactions leading to inflammation and angiogenesis. N - neural cell, MC - mast cell, PMN - 
polymorphonuclear leukocyte, EC - endothelial cell, SP - substance P, and CGRP - calcitonin gene-related peptide (these 
are shown as examples of well-known proinflammatory neuropeptides), IL-1 - interleukin-1, bFGF - basic fibroblast growth 
factor. For the rest abbreviations, see the text. 
  
 
Figure 4. Cell-mediator interactions leading to proliferation and fibrosis. N - neural cell, MC - mast cell, F - fibroblast, 
TGF-f} - transforming growth factor-^, Ang 11 - angiotensin II. Note: (i) substance P exerts mitogenic effect both on 
fibroblasts and smooth muscle cells (31,32), and (ii) MC may also produce collagen (33). 
  
Table 2. Mast cell-derived molecules as yin-yang modulators 
in inflammation and fibrosis 
 
*Note: this molecule may have both yin and yang potential. 
VIP - vasoactive intestinal polypeptide, NO - nitric oxide. 
diovascular diseases of inflammatory-fibroproliferative nature 
(11,43). Perhaps, "we are already beginning to witness the 
change" (39) in our understanding of inflammation and fibro- 
sis, as well as other nerve-MC-NGF-associated phenomena. A 
few years ago, it would seem premature to think that the sub- 
mandibular gland, the richest source of NGF and a densely in- 
nervated effector tissue that also contains significant amount 
of MC, may produce molecules involved in regulation of in- 
flammatory (44, also see Mathison [45] in this volume of Bio- 
medical Reviews) and behavioral (46,47) responses. In effect, 
optimization of mechanisms for maintaining and/or restoring 
nerve-MC-NGF-MGFhomeostatic functions following tissue 
inflammatory stimuli may lead to the development of new, MC- 
directed therapies for inflammatory-fibroproliferative diseases. 
Examples include angiotensin-converting enzyme inhibitors 
(21), MC stabilizing drugs (24,38), opioid receptor antagonists 
(36), anti-TNF-a drugs (48-51), adenosine A3-receptor antago- 
nists (52), histamine H3-receptor agonists (53), and tryptase in- 
hibitors (54). 




Biomed Rev 4,1995 
Chaldakov, Ghenev, Valchanov, Tonchev, and Pancheva 
  
Of course, the questions to be addressed remain rather more 
than the answers provided. This, in view of the Szent-Gyorgyi's 
thought at the beginning of this Editorial, means that we al- 
ready are aware of the names of dozens of cells and molecules 
that govern inflammation and fibroproliferation. And, hope- 
fully, we are forwarding to the hundred and first name. 
In further studies we would try to pursue whether MC will 
prove to stand for "master cell" (1), "the immune gate to the 
brain" (55), and yin-yang modulator in inflammation and fi- 
brosis. And, even more intriguing is whether the inflamma- 
tory-fibroproliferative response is at least in part a neural- 
mastokine phenomenon. 
















laboratory of Electron Microscopy, 
Department of Anatomy and Histology, 
^Department of General and Clinical Pathology, 




1.     Galli SJ. New concepts about the mast cell. New Engl J 
        Meet 1993; 328:257-265 . 
2.     Marshall JS, Bienenstock J. The role of mast cells in in- 
flammatory reactions of the airways, skin and intestine. 
Curr Opin Immunol 1994; 6: 853-859 
3.    Williams RM, Bienenstock J, Stead RH. Mast cells: the 
neuroimmune connection. In: Marone G, editor. Human 
basophils and mast cells: biological aspects. Chem 
Immunol 1995; 61: 208-235 
4.    Aloe L, Tuveri M-A, Angelucci F. Nerve growth factor, 
mast cells and arthritis. BiomedRev 1995; 4: 7-14 
5.     Leon A, Buriani A, Toso RD, Fabbi M, Romanello S, Aloe 
L. Mast cells synthesize, store, and release nerve growth 
factor. Proc Natl Acad Sci USA 1994; 91: 3739-3743 
6.     Harvima IT, Horsmanheimo L, Naukkarinen A, Horsman- 
heimo M. Mast cell proteinases and cytokines in skin 
inflammation. Arch Dermatol Res 1994; 287: 61-67 
7.     Aloe L, Levi-Montalcini R. Mast cells increase in tissues 
of neonatal rats injected with the nerve growth factor. 
Brain Res 1977; 133: 358-366 
 
Biomed Rev 4,1995 
8.     Levi-Schaffer F, Rubinchik E. Mast cell/fibroblast inter- 
actions. Clin Exp Allergy 1994; 24: 1016-1021 
9.     Bankl HC, Radaszkeiwicz T, Valent P. Mast cells and 
mast cell growth factor: possible role in auricular throm- 
bosis. BiomedRev 1995; 4: 29-34 
10.   Carnahan IF, Patel DR, Miller JA. Stem cell factor is a 
neurotrophic factor for neural crest-derived chick sen- 
sory neurons. JNeurosci 1994; 14: 1433-1440 
11.   Chaldakov GN, Ghenev PI, Andonov M, Valchanov K, 
Tonchev A, Pancheva R. Neural-immune-effector (NIE) 
cross-talk in vascular trophobiology: proposal for new 
and not yet exploited purinergic regulatory mechanisms. 
BiomedRev 1994; 3: 81-86 
12.  Aloe L, Skaper SD, Leon A, Levi-Montalcini R. Nerve 
growth factor and autoimmune diseases. Autoimmunity 
1994; 19: 141-150 
13.  Marshall JS, Waserman S. Mast cells and the nerves - 
potential interactions in the context of chronic disease. 
Clin Exp Allergy 1995; 25: 102-110 
14.  Warner JA, Kroegel C. Pulmonary immune cells in health 
and disease: mast cells andbasophils. EurRespirJ 1994; 
7: 1326-1341 
15.  Changqing Z, Zhengde T, Jianyun X, Suping Z, Jiantian 
Q. An immunocytochemical study on relations between 
mast cell and peptidergic terminals in nasal mucosa of 
chronic rhinitis patients. Chin Med J 1995; 108: 606- 
609 
16.  Matsson L, Norevall L-I, Forsgren S. Anatomic relation- 
ship between substance P- and CGRP-immunoreactive 
nerve fibers and mast cells in the palatal mucosa of the 
rat. EurJOralSci 1995; 103: 70-76 
17.   Dimitriadou V, Henry P, BrochetB, Mathiau P, Aubineau 
P. Cluster headache: ultrastructural evidence for mast cell 
degranulation and interaction with nerve fibres in the hu- 
man temporal artery. Cephalalgia 1990; 10: 221-228 
18.  Aubineau P, Mathiau P. Can vascular headaches be trig- 
gered by the autonomic nervous system? In: Bevan RD, 
Bevan JA, editors. The human brain circulation. Humana 
Press, 1994; 433-444 
19.   Weber S, Krtiger-Krasagakes S, Grabbe J, Zuberbier T, 
CzarnetzkiBM. Mast cells. IntJDermatol 1995; 34:1-10 
20.   Goto T, Befus D, Low R, Bienenstock J. Mast cell het- 
4 
Nerve-mast cell-NGF link in inflammation and fibrosis 
  
erogeneity and hyperplasia in bleomycm-induced pulmo- 
nary fibrosis of rats. Am Rev Respir Dis 1984; 130: 797- 
802 
21.  Ramos SG, Montenegro AP, Goissis G, Rossi MA. 
Captopril reduces collagen and mast cell and eosinophil 
accumulation in pig serum-induced rat liver fibrosis. 
Pathollnt 1994; 44: 655-661 
22.   Atkinson JB, Harlan CW, Harlan GC, Virmani R. The 
association of mast cells and atherosclerosis: A morpho- 
logic study of early atherosclerotic lesions in young people. 
HumPathol 1994; 25: 154-159 
23. Kovanen PT, Kaartinen M, Paavonen T. Infiltrates of ac- 
tivated mast cells at the site of coronary atheromatous 
erosion or rupture in myocardial infarction. Circulation 
1995; 92: 1084-1088 
24.  Nagler A, Segal V, Slavin S, Levi-Schaffer F. Ketotifen 
therapy in chronic graft-versus-host disease (cGVHD): 
effect on mast cells and fibroblasts. Clin Exp Immunol 
1995; 100: 529-535 
25.   Nagai T, Takaba H, Miyake K, Hirabayashi Y, Yamada 
K. Testicular mast cell heterogeneity in idiopathic male 
infertility. Fertil Steril 1992; 57: 1331-1336 
26.   Theoharides TC, Flaris N, Cronin CT, Ucci A, Meares 
E. Mast cell activation in sterile bladder and prostate in- 
flammation. Int Arch Allergy Appl Immunol 1990; 92: 
281-286 
27.   Gorospe JR, Tharp MD, Hinckley J, Kornegay JN, 
Hoffman EP. A role for mast cells in the progression of 
Duchenne muscular dystrophy? Correlations in dystro- 
phin-deficient humans, dogs, and mice. JNeural Sci 1994; 
122: 44-56 
28.   Meininger CJ, Zertter BR. Mast cell and angiogenesis. 
Semin Cancer Biol 1992; 3: 73-79 
29.   Qu Z, Eiebler JM, Powers MR, Galey T, Ahmadi P, 
Huang X-N, et al. Mast cell are a major source of basic 
fibroblast growth factor in chronic inflammation and cu- 
taneous hemangioma. Am J Pathol 1995; 147: 564-573 
30.   Brown JK, Tyler CE, Jones CA, Ruoss SJ, Hartmann T, 
Caughey GH. Tryptase, the dominant secretory granular 
protein in human mast cells, is a potent mitogen for cul- 
tured dog tracheal smooth muscle cells. Am J Respir Cell 
Mol Biol 1995; 13:227-236 
31.   Nilsson J, von Euler AM, Dalsgaard CJ. Stimulation of 
connective tissue cell growth by substance P and sub- 
stance K. Nature 1985; 315: 61 
32.  Payan DG. Receptor-mediated mitogenic effects of sub- 
stance P on cultured smooth muscle cells. Biochem 
BiophysRes Commun 1985; 130: 104 
-./ 
33.  Ruger B, Dunbar PR, Hasan Q, Sawada H, Kittelberger 
R, Greenhill N, et al. Human mast cells produce type VTfl 
collagen in vivo. Int J Exp Pathol 1994; 75: 397-404 
34.   H0gasen AKM, Abrahamsen TG. Heparin suppresses li- 
popolysaccharide-induced monocyte production of sev- 
eral cytokines, but simultaneously stimulates C3 produc- 
tion. ThrombRes 1995; 80: 179-184 
35.   Moran CS, Campbell JH, Simmons DE, Campbell GR. 
      Human leukemia inhibitory factor inhibits development 
      of experimental atherosclerosis. Atheroscler Thromb 
      1994; 14: 1356-1363 
36.  Tuncel N. Mast cells, vasoactive intestinal peptide (VJP), 
and the hemorrhagic shock: a possible relationship? 
BiomedRev 1993; 2: 37-46 
37.   Saarinen J, Kalkkinen N, Welgus HG, Kovanen PT. Ac- 
tivation of human interstitial procollagenase through di- 
rect cleavage of the Leu -̂Thr
84
 bond by mast cell chymase. 
JBiol Chem 1994; 269: 18134-18140 
38.   Kanwar S, Kubes P. Ischemia/reperfusion-inducedgranu- 
locy te influx is a multistep process mediated by mast cells. 
Microcirculation 1994; 1: 175-182 
39. Blalock JE. The syntax of immune-neuroendocrine com- 
munication. Immunol Today 1994; 15: 504-511 
40.   Sperr WR, Bankl HC, Mundigler G, Klappacher G, 
GroBschmidt K, Agis H, et al. The human cardiac mast 
cell: localization, isolation, phenotype, and functional 
characterization. Blood 1994; 84: 3876-3884 
41. Korsching S, Thoenen H. Nerve growth factor in sympa- 
thetic ganglia and corresponding target organs of the rat: 
Correlation with density of sympathetic innervation. Proc 
NatlAcadSci USA 1983; 80: 3513-3516 
42.  Donovan MJ, Miranda RC, Kraemer R, McCaffrey TA, 
Tessarollo E, Mahadeo D, et al. Neurotrophin and neuro- 
trophin receptors in vascular smooth muscle cells. Regu- 
lation of expression in response to injury. Am J Pathol 
1995; 147: 309-324 
43.  Chaldakov GN, Valchanov K, Tonchev A, Ghenev PI. 
  
5 
Biomed Rev 4,1995 
The association of mast cells and atherosclerosis: new 
insights into mast cells in atherogenesis [letter]. Hum 
Pathol 1995; 26: 1286 
44.   MathisonR, DavisonJS, Befus AD. Neuroendocrineregu- 
lation of inflammation and tissue repair by submandibu- 
lar gland factors. Immunol Today 1994: 15: 527-532 
45.  Mathison R. The submandibular glands: a role in ho- 
meostasis and allostasis. Biomed Rev 1995; 4: 61-69 
46.   Alleva E, Aloe L, Bigi S. An updated role for nerve growth 
factor in neurobehavioural regulation of adult vertebrates. 
RevNeurosci 1993; 4: 41-62 
47.   Chaldakov GN, Valchanov K, Tonchev A. Neural-im- 
mune-effector trophobiology: possible implications in 
psychology of the allergic patient [letter]. Allergy. In press 
48.   Chaldakov GN. Antitubulins - a new therapeutic approach 
for atherosclerosis? Atherosclerosis 1982; 44: 385-390 
49.   Tiegs G, Freudenberg MA, Galanos C, Wendel A. Colchi- 
cine prevents tumor necrosis factor-induced toxicity in 
vivo. Infection Immunol 1992; 60: 1941-1945 
50.  Chaldakov GN. An antitumour necrosis factor therapy. 
AIDS 1992; 6: 439-440 
51.   Anaya J-M, Espinoza LR. Phosphodiesterase inhibitor 
    pentoxifylline: An antiinflammatory/immunomodulatory 
    drug potentially useful in some rheumatic diseases. J 
    Rheumatol 1995; 22: 595-599 
52.   Linden J. Cloned adenosine A, receptors: pharmacologi- 
cal properties, species differences and receptor functions. 
TrendsPharmacol Sci 1994; 15: 289-306 
5 3. Dimitriadou V, Rouleau A, Tuong MDT, Newlands GIF, 
Miller HRP, Luffau G. et al. Functional relationship be- 
tween mast cells and C-sensitive nerve fibers evidenced 
by histamine H,-receptor modulation in rat lung and 
spleen. C/m 5c/1994; 87: 151-163 
54.   Tanaka RD, Clark JM, Warne RL, Abraham WM, Moore 
WR. Mast cell tryptase: a new target for therapeutic in- 
tervention in asthma. Int Arch Allergy Immunol 1995; 
107:408-409 
55.   Theoharides TC. Mast cells: the immune gate to the brain. 









Biomed Rev 4,1995 
Chaldakov, Ghenev, Valchanov, Tonchev, and Pancheva 
6 
